Risk and Management of Patients with Mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) Pandemic: Expert Opinions *
The COVID-19 (SARS-CoV-2) pandemic has massively distorted our health care systems and caused catastrophic consequences in our affected communities. The number of victims continues to increase and patients at risk can only be protected to a degree, since the virulent state may be asymptomatic. Risk factors concerning COVID-19-induced morbidity and mortality include advanced age, an impaired immune system, cardiovascular or pulmonary diseases, obesity, diabetes mellitus, and cancer treated with chemotherapy.
Source: Journal of Allergy and Clinical Immunology - Category: Allergy & Immunology Authors: Peter Valent, Cem Akin, Patrizia Bonadonna, Knut Brockow, Marek Niedoszytko, Boguslaw Nedoszytko, Joseph H. Butterfield, Ivan Alvarez-Twose, Karl Sotlar, Juliana Schwaab, Mohamad Jawhar, Andreas Reiter, Mariana Castells, Wolfgang R. Sperr, Hanneke C. Klui Source Type: research
More News: Allergy | Allergy & Immunology | Cancer | Cancer & Oncology | Cardiology | Cardiovascular | Chemotherapy | COVID-19 | Diabetes | Diabetes Mellitus | Eating Disorders & Weight Management | Endocrinology | Health Management | Heart | Obesity | Pandemics | SARS